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Introduction:
Acute decompensated heart failure (ADHF) is a serious problem affecting over 1,000,000 Americans annually and is the most common hospital discharge diagnosis among Medicare beneficiaries. 1 A diagnosis of ADHF carries with it a poor prognosis with a one-year post-discharge mortality of 33%. [2] [3] [4] Six month readmission rates stand near 50%, reflecting the challenging problem of effectively managing ADHF. 5 The economic burden associated with ADHF is substantial and accounts for more than half of all heart failure expenditures. 6 To date, ADHF research has enjoyed limited success aside from the description of the poor survival associated with this condition. 7 Underlying the challenge in treating ADHF are the complex pathophysiologic mechanisms involved in its genesis. On a fundamental level, ADHF is predominantly a disease of congestion and volume overload. 8, 9 Patients suffering from ADHF often present with signs of excess volume such as peripheral edema, jugular venous distention, and dyspnea. Consequently, returning patients to a euvolemic state remains the primary treatment goal and one of the strongest predictors of survival in patients with heart failure. 10, 11 The presence of volume overload likely plays a pathologic role and directly contributes to heart failure disease progression. 12 Venous congestion leads to increased sympathetic activity and activation of the renin-angiotensin-aldosterone system (RAAS), both of which increase cardiac strain and induce pathologic remodeling of the myocardium. 13 From a clinical standpoint, neurohormonal activation leads to progression of heart failure and worse outcomes. 14 Taking all of this information into consideration, finding effective treatments paradigms to remove volume in ADHF has been a top priority.
therapy in congestive heart failure. 15 While treatment with loop-diuretics proves to be effective, there are limitations and drawbacks to its intensive and prolonged use. 16 Loopdiuretics inherently function to induce volume loss through natriuresis. One earlyidentified phenomenon was that repeated dosing results in reduced natriuresis and efficacy of the subsequent dose. This occurs on a dose-to-dose basis in a phenomenon known as diuretic braking. 17 It also occurs on a long-term, progressive basis which is termed diuretic resistance. 18 Both of these issues arise from renal compensation stemming from exposure to loop-diuretics. Increased sodium delivery to the tubule with diuretic therapy results in tubular hypertrophy, increased sodium absorption, and decreased diuretic responsiveness. 18, 19 Furthermore, neurohormonal activation in response to diuretic therapy supports the tubular and vascular compensatory mechanisms that result in increased sodium avidity by the kidney and decreased diuretic responsiveness. To reach the important goal of decongestion, the dose of loop-diuretics is increased to overcome resistance. However, increased doses of loop-diuretics are linked to neurohormonal activation, and poorer outcomes. 20, 21 Consequently, new heart failure treatment strategies must consider maintaining responsiveness to loop-diuretics while aiming to effectively remove excess fluid.
Guideline directed medical therapies (GDMT) temper the negative effects of neurohormonal activation that is the consequence of both ADHF physiology and diuretic therapy. Accordingly, initiating and increasing the dosages of these medications is another important goal recommended by heart failure guidelines to reduce mortality and disease progression. [22] [23] [24] The primary GDMTs include angiotensin converting enzyme inhibitors (ACE-Is), Angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs). Inhibition of the renin-angiotensinaldosterone-system with ACE-Is reduces mortality, and this effect has been repeatedly proven in large clinical trials. [25] [26] [27] For patients who cannot tolerate ACE-Is, ARBs can be utilized as several large studies validated that they are comparable in efficacy. 28, 29 Both of these medicines work to reduce mortality in heart failure by several mechanisms, many of which are still in the process of being studied. One readily observed action of ACEIs/ARBs is to lower blood pressure, counteracting the vasoconstrictive effects and increased sodium reabsorption resulting from RAAS activation. RAAS mediated cardiac fibroblast proliferation and cardiomyocyte apoptosis that cause ventricular remodeling are also likely reduced both by lowering blood pressure and by the direct action of these medications on cardiac tissue. 30, 31 However, side effects of these medications include cough (with ACE-Is), hyperkalemia, and a decrease in GFR. Beta-blockers are another important pillar of heart failure therapy. They are a longstanding component of therapy,
and their use in heart failure is supported by multiple, large studies in the literature. [32] [33] [34] These medications work by inhibiting different elements of beta-adrenergic activation, reducing cardiac strain and oxygen consumption by lowering heart rate and cardiac contractility. 34 Finally, spironolactone and eplerenone are MRAs that function by displacing aldosterone from the mineralocorticoid receptor in the collecting duct of the nephron. Eplerenone additionally has been shown to reduce the aldosterone-mediated cardiac remodeling, demonstrating the advantages drawn from the direct effect of these medications on cardiac tissues. 35 As such, their use is recommended by guidelines following major trials that demonstrated a survival benefit with the use of MRAs in heart failure. [36] [37] [38] One consideration with the use of GDMT is the reduction of blood pressure caused by these therapies. The systolic blood pressure (SBP) decreases in response to ADHF therapy through combinations of the direct vascular effects of the medications, reduced cardiac contractility, and volume reduction. In some ways, this is a desirable outcome, and chronic therapies are tailored to reduce longstanding elevations in blood pressure. Hypertension is a common co-morbidity in heart failure, and on a chronic basis is associated with adverse cardiovascular morbidity and mortality. Accordingly, society guidelines recommend lowering blood pressure to improve cardiovascular outcomes and survival. 22 However, short-term reductions in blood pressure during hospitalization for ADHF may be antagonistic to the primary acute goals of ADHF therapies.
An emerging signal is that a decline in blood pressure during hospitalization strongly links to worsening renal function (WRF) during the treatment of ADHF. [39] [40] [41] [42] WRF is an adverse outcome in heart failure, and is often defined in the literature as either a >20% decrease in GFR or a creatinine increase of 0.3 mg/dL. 43 Initial studies of WRF discovered that WRF was both a common feature in heart failure, and associated with a worse prognosis. 44 Relatedly, cardiorenal syndrome develops frequently in patients with heart failure. Cardiorenal syndrome is defined by a decrease in kidney function associated with heart failure. This loose definition incorporates kidney disease leading to cardiovascular disease, acute kidney injury in response to hear failure, and primarily, compromise of kidney function secondary to congestive heart failure. 45 Originally, decreases in cardiac output and blood pressure secondary to the hemodynamic derangements of heart failure were thought to decrease renal perfusion and lead to damage. However, venous congestion has proven to more closely correlate with WRF while parameters of cardiac output poorly associate with WRF. 46, 47 This new paradigm links the unfavorable prognosis seen with congestion, neurohormonal activation, and WRF. As our understanding of the cardiorenal syndrome grows, new opportunities are realized for improving ADHF outcomes.
It has become apparent that the cause of WRF is of more prognostic relevance than WRF itself. 43 Notably, WRF associated with SBP-reduction proved to be a phenotype not linked to worse prognosis, thus demonstrating the need for a better understanding of the relationship between blood pressure and WRF during ADHF. 42 Normally, maintenance of GFR across a wide range of blood pressures occurs primarily through renal autoregulation at the level of the glomerulus. The two primary mechanisms employed by the kidney to maintain GFR are tubuloglomelular feedback (TGF) and myogenic feedback. Both of these mechanisms ensure protection of the delicate glomerulus during periods of elevated blood pressure and maintenance of GFR as blood pressure decreases. TGF works by utilizing the macula densa to infer changes in blood pressure through the distal tubule flow. Nevertheless, recent data indicates that the myogenic response is the primary autoregulatory mechanism, especially in protecting the glomerulus from increases in blood pressure. 48 The myogenic response acts by measuring perturbations in blood pressure through stretch receptors in the afferent arteriole.
Vascular tone of the afferent arteriole is then either increased or decreased in response to high or low blood pressure, respectively. The predominance of the myogenic response to fluctuations in blood pressure explains why GFR is predominantly pressure dependent rather than flow dependent. 49 Moreover, it has been demonstrated that changes in systolic blood pressure, rather than diastolic blood pressure, is the primary stimulus for the myogenic autoregualtion. 48 Despite the robust autoregulation seen in normal subjects, the GFR of ADHF patients is linked closely with changes in blood pressure. Congestive heart failure presents a unique environment in which the mechanisms for autoregulation are impaired. 50 Often this is attributable to damage of the regulatory mechanisms that occur with common co-morbidities of heart failure. Longstanding hypertension leads to pathologic remodeling of the afferent arteriole which subsequently damages the ability to autoregulate. 51 Furthermore, the presence of diabetes can lead to alterations in both the vascular and possibly tubular components of renal autoregulation. When examining the components of ADHF therapy, and their physiologic manifestations, the question arises whether they can ever be counterproductive. Many of the therapies currently employed in ADHF result in a reduction in blood pressure.
Guidelines recommend using hospitalization for ADHF as an opportunity to optimize or initiate chronic oral medications such as beta-blockers, ace-inhibitors, and vasodilators, leading to the opportunity for further iatrogenic reduction in blood pressure. 23, 24, 53 Given that a reduction in blood pressure during the treatment of ADHF is strongly associated with WRF, and considering the kidney is the primary conduit by which volume is removed, it is unclear if elective titration of vasodilators and neurohormonal antagonists may be contrary to the immediate goal of fluid removal in ADHF. Society guidelines do not address how, or if, these goals can be achieved simultaneously due to the paucity of evidence on the subject in the current literature.
Statement of Purpose:
To date, there is little research outlining the effect that initiating or increasing GDMT has on diuretic therapy during ADHF hospitalization. An important element to this puzzle is whether changes in systolic blood pressure impact diuresis with loop-diuretics. Especially when considering the failure of renal autoregulatory mechanisms in ADHF and the high rates of WRF as blood pressure decreases. Despite these challenges, further research is necessary to allow for evidence-based decision making for clinicians treating heart failure patients. This study acts as a first step in directly addressing this issue.
Aim 1: Determine whether a decrease in blood pressure from admission to discharge will affect decongestion as assessed by diuretic efficiency
Hypothesis 1: SBP-reduction, defined as a greater than median decrease in SBP from admission to discharge, will not reduce diuretic efficiency Aim 2: Investigate the effect of initiating or titrating guideline recommended medications during hospitalization on blood pressure, renal function, and decongestion.
Hypothesis 2: GDMTs will increase rates of blood-pressure reduction and WRF, but will not affect diuretic efficiency.
Methods:
The study population was drawn from consecutive admissions to the Hospital of the This previously utilized definition accounts for the non-linear relationship between renal function and serum creatinine. 43, 55 Conversely, improvement in renal function (IRF) was 
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Loop diuretic doses were converted to furosemide equivalents with 1mg bumetanide = 20 mg torsemide = 80 mg furosemide for oral doses, and 1mg bumetanide = 20 torsemide = 40 furosemide for intravenous doses. 57, 58 The total loop diuretic given during hospitalization is the sum of the total oral and IV loop diuretics given from admission to discharge. Diuretic efficiency (DE) was calculated by dividing the total net output during hospitalization by total IV loop-diuretic dose (40mg IV furosemide equivalents) during hospitalization. 59 High diuretic efficiency was defined as values above the median. For medication analysis, angiotensin converting enzyme inhibitors (ACE-Is) were converted to lisinopril equivalents and Angiotensin II receptor blockers (ARBs) were converted to losartan equivalents for comparison.
Statistical analysis:
Values are reported as Mean ± standard deviation or median with interquartile range for continuous variables, and proportion (%) for discrete variables. (20) .
Project Responsibilities:
The student (Kula) was responsible for the majority of the activities related to this 
Results:
Baseline variables and change in blood pressure:
Baseline characteristics for the cohort are presented in Table 1 . Overall, 77.6%
of patients had a discharge SBP lower than the admission value, which translated into a median absolute SBP-reduction of 12.3 mmHg (IQR -25.3 to -1.7). The median relative reduction in SBP was 9.9% (IQR 18.2 to 1.4). Patients with SBP-reduction on average had higher baseline SBP, HR, and a lower EF. Notably, baseline medications were similar across all groups with the exception of the loop diuretic dose, which tended to be lower in the SBP-reduction group (Table 1) .
Relationship between SBP reduction, renal function, and diuresis
Similar to previous observations, SBP-reduction was associated with WRF (OR Despite the association with deteriorations in renal function, SBP-reduction did not appear to limit decongestion ( Table 2) Table 2 ). The extent of SBP reduction did not influence diuretic efficiency (p=0.58 for variation across all quintiles of relative decline in SBP) ( Figure 5 ).
Further investigation examined the relationship between SBP-reduction, renal function, and decongestion stratified by whether the patient's admission SBP was above or below the median value (now referred to as 'higher admission SBP' or 'lower' CI: 2.3-4.3, p<0.001). There was no significant difference in the rates of WRF with SBPreduction for those with a lower admission SBP Table 3 . However, SBP-reduction was associated with WRF in patients with a higher admission SBP (OR WRF: 2.3, 95% CI:
1.2-4.3, p=0.012). Notably, diuretic efficiency was similar for all groups. SBP-reduction did not reduce diuretic efficiency whether it was in the context of a lower or higher admission SBP Table 3 . The lack of association between SBP-reduction and diuretic efficiency remained in regression models when adjusting for admission SBP value (OR:
1.24, 95% CI: 0.9-1.7, p=0.209). Models including the relative decline in SBP during hospitalization (continuous) and admission SBP value yielded similar results (OR: 1.11
per 10% decrease in SBP admission to discharge, 95% CI: 0.97-1.3, p=0.115).
SBP-reduction and survival
In a univariate model, SBP-reduction was associated with a survival advantage 
Titration of Medications and measures of diuresis/decongestion
Guideline directed medical therapies (GDMTs) did not result in higher incidence of WRF or compromise DE Table 4 . Analysis compared patients continuing or increasing (including a new start on the medication) the dosage of their medications versus those who decreased, stopped, or never took the medications.
ACE-I and/or ARBs:
The dosage of ACE-I or ARBs was continued or increased in 71% (n=466) of patients.
7.2% (n=47) of the study population had their ACE-I or ARB stopped anytime during admission. ACE-Is and/or ARBs did not increase the rates of WRF during hospitalization (OR: 0.90, 95% CI: 0.7-1.4, p=0.903) or at discharge (0.82, 95% CI: 0.5-1.3, p=0.395).
However, ACE-Is or ARB use was strongly associated with high DE in both unadjusted (OR: 2.7, 95% CI: 1.9-3.8, p<0.0001) and adjusting for relevant baseline variables such as age, sex, hematocrit, hemoglobin, BNP, creatinine, and sodium, eGFR, ejection fraction, hypertension, diabetes, baseline ace-inhibitor or ARB, beta-blocker, thiazides, and hydralazine usage (OR: 1.99, 95% CI: 1.3-3.1, p=0.002).
Beta-Blockers:
A vast majority (88%, no=577) of the study population had their beta-blocker dosage continued at the same dosage or increased. Beta-blocker use in this group was 
Mineralocorticoid Receptor Antagonists:
Spironolactone was compared between patients newly started or continuing (22%, n=148) versus those who either did not receive the medication or it was discontinued during hospitalization. Spironolactone was not associated with SBP-reduction (OR: 0.98, 95% CI: 0.7-1.4, p=0.925) and similarly was not associated with WRF or high diuretic efficiency.
GDMT combinations:
Continuing and/or increasing the dosages ACE inhibitors/ARBs and beta-blockers occurred in 63% (n=417) of the study population. 
GDMT and Mortality:
No individual medication or combination of GDMT was associated with higher mortality in both unadjusted and adjusted models. The extent to which these medications afforded a survival benefit varied, and is summarized in Table 5 and Figure 8 . 
Discussion
The present study demonstrates that a reduction in SBP was associated with deteriorations in renal function without compromising diuresis and decongestion. SBP decreased in the majority of patients during hospitalization, and for those with a reduction in SBP greater than the median, the risk for WRF doubled. Nonetheless, there was no reduction in a wide array of metrics of decongestion including diuretic efficiency and hemoconcentration. Furthermore, patients starting, continuing, or increasing dosages of GDMT were more likely to have a reduction in blood pressure, an overall improvement in diuretic efficiency, and better prognosis.
The link between reductions in SBP and WRF is becoming an accepted principle in cardiorenal pathology. [40] [41] [42] Several physiologic mechanisms exist to explain the increased rates of WRF with SBP-reduction. The intricate autoregulation of glomerular blood flow by the kidney serves to maintain GFR over a wide range of blood-pressures. 61 However, the physiologic environment of congestive heart failure and ADHF therapy often disrupt this intricate balance, leading to deterioration in GFR. Longstanding medical comorbities such as diabetes and hypertension in addition to blood-pressure medications and diuretics can compromise renal autoregulation. [50] [51] [52] The end result being that the kidney cannot appropriately respond to a decrease in blood pressure, leading to a decrease in GFR. Undoubtedly the high incidence of all of these factors in the study cohort led to the coupling of SBP-reduction and WRF seen in our analysis. Further highlighting the importance of these physiologic processes was the finding that patients with a higher admission SBP were more likely to develop WRF with SBP-reduction while patients with lower admission SBP had similar rates of WRF, regardless of SBPreduction.
Beyond the direct effect on GFR, little is known about the consequences of reducing SBP on treatment efficacy. As long as diuretic therapy remains the mainstay of decongestion in ADHF, the kidney will serve as the conduit for volume removal and as such any factors that affect kidney function could in theory compromise diuretic therapy.
However, the results of our study suggest that SBP-reduction minimally effects diuretic efficiency during hospitalization. Diuretic efficiency was used to define treatment success because it has been proven to be an indicator of how effective the diuresis is during hospitalization and has prognostic significance. 59 To ensure that study participants were not just diuresing well, but returning to a euvolemic state, rates of hemoconcentration were examined. Hemoconcentration can be used as a marker for decongestion, the primary treatment goal in ADHF, and is associated with better survival. 62 As such, SBPreduction did not hinder the important goal of aggressive and complete decongestion.
SBP-reduction was not linked to worse outcomes in our analysis. This result builds upon recent evidence demonstrating that WRF associated with SBP-reduction was not associated with worse outcomes. 42 Several new concepts in ADHF research exist to help explain our findings in regards to prognosis. Firstly, the etiology of WRF is more relevant in determining prognosis than WRF taken alone. Therefore, the mechanisms by which SBP-reduction results in WRF may play less of a pathologic role in the progression of heart failure then other processes such as venous congestion or high dosages of loop-diuretics. Another important consideration for the low prognostic significance of SBP-reduction is the minor effect SBP-reduction had on therapy. It did not impede one of the primary determinants of disease progression and survival, thorough decongestion.
Another finding of this study was that starting, continuing, or increasing the dose of guideline medications was possible without impeding decongestion. GDMT use in this manner led to higher rates of SBP-reduction, which was to be expected considering these are antihypertensive medications. The controlled environment of hospitalization provides a perfect opportunity to optimize dosages. Consequently, it is encouraging that in this analysis all combinations of GDMT did not at any time reduce diuretic efficiency or survival.
One unexpected result was the lack of association between continuing and/or increasing GDMT, especially ACE-I and ARBs, with WRF. While this result was not anticipated, other ADHF studies also noted a lack of association between ACE-I/ARBs and WRF during hospitalization. 63, 64 One explanation could be that an ADHF hospitalization presents a unique environment due to venous congestion, and subsequent aggressive diuretic therapy, altering renal autoregulation and increasing neurohormonal activation. In this context, the effect of ACE-Is and ARBs impart on GFR may be masked, or the effect could in some ways be protective by tempering the renal compensatory mechanisms in response to diuretic therapy. 65 From a clinical practice standpoint, it was notable that any combination of GDMT (ACE-I/ARB, beta-blockers, spironolactone) did not reduce DE in our analysis. ACE-I/ARBs, alone or in combination with beta-blockers, were associated with high DE. Higher DE with ACE-I/ARB use likely represents the direct effect of the drug lessening the hemodynamic and tubular changes in response to loop-diuretic therapy. Notably, a study by Chen et. Al.
demonstrated that furosemide-induced diuresis was substantially enhanced by the addition of losartan. 66 Neurohormonal activation, which ACE-Is and ARBs partially block, play an important role in blunting the response to loop-diuretics by increasing the sodium avidity of the kidney. Reducing the tubular compensation and neurohormonal activation, which has repeatedly associated with worse outcomes, may be of greater importance to some extent than maintaining the autoregulation of glomerular blood flow and GFR. Just as increases of WRF secondary to a reduction in SBP result in a better prognosis, WRF associated with ACE-I use affords better outcomes than spontaneously occurring WRF. 67 Taken as a whole, this investigation found that the society guideline recommended goals of aggressive decongestion and initiation and optimizing of medical therapy were compatible. SBP-reduction, a common result of both of these goals, did not affect treatment success or survival. Relatedly, the survival benefits afforded by GDMT were true in this cohort and did not come at the cost of DE or WRF. Current guidelines recommend the aforementioned goals to increase survival, but lack details on how best to consolidate therapies. 23, 24, 53 Our analysis suggests this is generally possible, but more study is needed to understand the specifics. Further research will strengthen the fund of knowledge and, in turn, improve the detail of guideline recommendations and clinical decision-making.
Limitations:
Given the post-hoc retrospective nature of this analysis, uncontrolled confounding cannot be excluded. SBP values for admission were the average of the first three values in the patient record, and these values came both from the emergency department and patient room after admission. Therefore it is possible that some therapy (diuretics, bloodpressure medications, inotropes, etc..) were administered between the first and third reading and could have influenced the final blood pressure values. The direct effect that day-to-day changes in SBP may have on diuresis cannot be assessed, as daily blood pressures and fluid output were not recorded in the database on a daily basis. Conclusions in this study were drawn over an entire hospitalization, and therefore specific changes in clinical values, or changes in therapy in response, may confound the data in a way that cannot be accounted for. Relatedly, only starting and stopping doses over the course of hospitalization for GDMT medications were used for analysis. Daily changes to the dosages of medications, the reason for these changes, and the effect these changes had on blood pressure, renal function, and diuretic efficiency, which could be used to guide therapy, were not part of this study. Relatedly, tailoring of the therapy could have altered the outcomes over the course of hospitalization. As a result of these limitations these findings should be regarded as hypothesis generating for future prospective studies.
Conclusion:
SBP-reduction is associated with WRF but does not limit decongestion in ADHF.
Continuing or increasing guideline direct medical therapy did not alter rates of WRF or diuretic success.
